Journal
EUROPEAN JOURNAL OF CELL BIOLOGY
Volume 91, Issue 1, Pages 53-58Publisher
ELSEVIER GMBH, URBAN & FISCHER VERLAG
DOI: 10.1016/j.ejcb.2011.01.012
Keywords
Dendritic cells; Young dendritic cells; Dendritic cell-based vaccines; Antitumor response; Memory effector cytotoxic T lymphocytes; Dendritic cell maturation; Th1-polarization
Categories
Funding
- German Research Foundation [SFB-455, SFB-TR36]
- European Union
- Helmholtz Society Alliance
- BayImmuNet Program
Ask authors/readers for more resources
This review summarizes our studies of the past several years on the development of third generation dendritic cell (DC) vaccines. These developments have implemented two major innovations in DC preparation: first, young DCs are prepared within 3 days and, second, the DCs are matured with the help of Toll-like receptor agonists, imbuing them with the capacity to produce bioactive IL-12 (p70). Based on phenotype, chemokine-directed migration, facility to process and present antigens, and stimulatory capacity to polarize Th1 responses in CD4(+). T cells, induce antigen-specific CD8(+) CTL and activate natural killer cells, these young mDCs display all the important properties needed for initiating good antitumor responses in a vaccine setting. (C) 2011 Elsevier GmbH. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available